The clinical merit of our study lies in providing a rationale for using GPX4 inhibitor RSL3 to develop non-apoptotic strategies for managing refractory or relapsed MM patients who have shown resistance to PIs. This evidence concerns the gene GPX4 and Miyoshi myopathy.